Origenis receives grant to develop new diagnostic tools for the treatment of neurodegenerative disorders

29-Feb-2012 - Germany

Origenis has started the development of biomarkers to complement the preclinical in-house development of its therapeutic small molecule inhibitors acting on LRRK2. LRRK2 inhibitors are expected to be useful for the treatment of Parkinson’s disease and other neurodegenerative disorders.

The objective of this biomarker program is the development of fluorine labelled, LRRK2 specific, CNS penetrating compounds that will be used to visualize the disease progression in animal Parkinson’s models.

Origenis receives a two-years-grant from the Leading-Edge Cluster program “m4 – Personalized Medicine and Targeted Therapies”.

Other news from the department research and development

Most read news

More news from our other portals

Recognise, understand, heal: The World of Diagnostics